document.writeln("
Matrix
to acquire Belgian drug firm Docpharma for $263 mn
Hyderabad: Matrix Laboratories Ltd (MLL) has decided
to acquire the Belgium-based $263-million pharma company
Docpharma NV, in what could be considered as the largest
ever acquisition executed by an Indian pharma company.
The announcement comes on the back of Hyderabad-based
Matrix Labs recent announcement of its plans to acquire
Strides Arcolab Ltd. The latest acquisition will enable
the Matrix-Docpharma combine to leapfrog into the premier
league of top-five Indian pharma majors.
MLL has signed a share purchase agreement with Docpharma
promoters for acquiring 13,70,085 shares, constituting
a controlling stake of around 22 per cent, at a price
of 34 euros per share. Matrix would go for a mandatory
public takeover bid for acquiring the balance 78 per cent
shares held by public through an all cash offer.
Matrix proposes to initially finance the transaction through
a combination of cash on hand and bank borrowings. It
proposes to consider, if required, raising funds in the
capital markets to reduce bank borrowings post-transaction.
Docpharma, a pharma sales and marketing major backed by
strong portfolio of around 130 registered dossiers in
the EU market, currently has presence in Belgium, Netherlands,
Italy and France, the Docpharma Chief Operating Officer,
Mr Stijn Van Rompay, told presspersons.
Matrix would retain Docpharma's brands and trade names
in their markets. Further, Matrix and Docpharma have agreed
that Leon Van Rompay and Stijn Van Rompay would remain
and CEO and COO of Docpharma, respectively.
Back
to News Review index page